Russia’s focus on domestic pharma production could shield it from sanctions’ effects
Russia’s pharma manufacturing is more focused on the domestic market due to its comparative lack of FDA and EMA approvals.
By
GlobalData Healthcare
Latest articles
All Articles
Injectable packaging: strain, bottlenecks and changing demand
Packaging is creating bottlenecks in producing injectable drugs, as the industry lacks the capacity to make and fill enough…
By
Oxurion discontinues the development of THR-687 despite promising preclinical data
Oxurion has announced that clinical trials for THR-687, its novel pharmacotherapy for diabetic macular oedema, will not continue.
By
NICE recommends use of digital therapeutic for insomnia
The UK’s National Institute for Health and Care Excellence (NICE) has endorsed the Sleepio digital therapeutic to treat insomnia.
By
Advancements in GA pipeline brings first wave of therapies closer to patients
Recent advancements in late-stage therapies for geographic atrophy have raised hopes of ushering in its first wave of therapies.
By
Entrance of novel therapies drives alpha-1 antitrypsin deficiency market growth
The alpha-1 antitrypsin deficiency (AATD) market in the US and Germany is expected to see significant growth from 2021…
By
Osteoarthritis pipeline shifting from analgesics to disease-modifying treatments
Conventional analgesics prescribed for osteoarthritis offer inadequate pain relief and are associated with several adverse events.
By
FDA’s complete response letter may cost HUTCHMED nearly $100m in potential sales
The US FDA has rejected a new drug application (NDA) from HUTCHMED for surufatinib for advanced neuroendocrine tumours (NETs).
By
Tislelizumab makes headway towards approval in ESCC but faces tough competition
Tislelizumab has been making strides towards approval for the treatment of second-line oesophagal squamous cell carcinoma (ESCC).
By